In previous First Word columns, I discussed the effects of SGLT2 inhibitors on the kidney to prevent progression of chronic ...

Life without a pancreas involves treatments to replace organ function. Learn how different surgical techniques affect overall ...

Annabel Samimy, an analyst from Stifel Nicolaus, has initiated a new Buy rating on Altimmune (ALT).Stay Ahead of the Market:Discover ...

This discovery changed the once fatal diagnosis of type 1 diabetes to a manageable disease. The importance ... later this factor was identified as glucagon. Since these pivotal discoveries ...

Stifel analyst Annabel Samimy initiated coverage of Altimmune (ALT) with a Buy rating and $18 price target The company is developing ...

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.

Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function ...